Orchard Therapeutics, a London, UK- and California, US-based biotechnology company dedicated to treating rare disorders through innovative gene therapies, completed a $110m (£85m) Series B financing.
The round was co-led by Baillie Gifford and ORI Capital with participation from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund. In conjunction with the financing, Simone Song, senior partner at ORI Capital, joined Orchard’s board of directors.
The company intends to use the funds to progress its pipeline, including the global launch of OTL-101, and to expand their manufacturing infrastructure and business development activity.
Led by Mark Rothera, CEO, Orchard is advancing its lead product, OTL-101, an autologous ex-vivo lentiviral gene therapy in development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare and life-threatening inherited disorder of the immune system. OTL-101 has been granted Breakthrough Therapy Designation by the FDA and is currently in late stage clinical development. The company’s pipeline includes other clinical and pre-clinical stage transformative gene therapies for immune deficiencies, including X-linked chronic granulomatous disease (X-CGD) and metabolic diseases, including MPS-IIIA and MPS-IIIB (Sanfilippo syndrome type A and type B).
Orchard works in partnership with some of the world’s leading centres in gene therapy, including University College London, Great Ormond Street Hospital for Children NHS Foundation Trust, the University of Manchester and Central Manchester University Hospitals NHS Foundation Trust, the University of California Los Angeles and Boston Children’s Hospital.